Ansa Anderson
Family Medicine · Marietta, GANPI 1376073015
Payments from drug & device makers
Across 203 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$407
- GSK$362
- Takeda Pharmaceuticals U.S.A., Inc.$317
- Lilly USA, LLC$286
- Pfizer$231
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,877100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $1,023 |
| AbbVie | 23 | $407 |
| GSK | 20 | $362 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $317 |
| Lilly USA, LLC | 16 | $286 |
| Pfizer | 10 | $231 |
| AstraZeneca | 14 | $211 |
| Optinose US, Inc. | 6 | $119 |
| Novartis | 5 | $116 |
| Amgen | 8 | $113 |
| Bayer | 5 | $107 |
| Axsome Therapeutics, Inc. | 5 | $104 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $66 |
| Esperion Therapeutics, Inc. | 3 | $61 |
| Abbott | 3 | $60 |
| Astellas Pharma US Inc | 2 | $39 |
| Johnson & Johnson(2 entities) | 2 | $37 |
| Exact Sciences | 2 | $34 |
| Merck | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,877 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 17 | $17,051 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,113 |
| Metoprolol Succinate | 13 | $193 |
| Amlodipine Besylate | 14 | $189 |
| Atorvastatin Calcium | 16 | $159 |
| Rosuvastatin Calcium | 21 | $133 |
| Diazepam | 12 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $286 | $17,05117 claims |
| GSKTrelegy Ellipta | $362 | $7,11311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Marietta
- Cedrice DavisMarietta$621K
- Irshad SyedMarietta$118K
- Mitzi RubinMarietta$103K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.